Kancera Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Kancera şirketinin toplam hissedar öz sermayesi SEK83.0M ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK95.6M ve SEK12.6M dir.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 75.70m
Eşitlik	SEK 83.00m
Toplam yükümlülükler	SEK 12.64m
Toplam varlıklar	SEK 95.64m

Son finansal sağlık güncellemeleri

Recent updates

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Aug 13

We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully

Dec 06

Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?

Jul 19

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Mar 08

We Think Kancera (STO:KAN) Can Afford To Drive Business Growth

Jun 29

We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely

Mar 08

Here's Why We're Watching Kancera's (STO:KAN) Cash Burn Situation

Aug 02

We're Not Very Worried About Kancera's (STO:KAN) Cash Burn Rate

Apr 06

Here's Why We're Not Too Worried About Kancera's (STO:KAN) Cash Burn Situation

Dec 21

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: KAN 'nin kısa vadeli varlıkları ( SEK77.6M ) kısa vadeli yükümlülüklerini ( SEK12.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: KAN un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: KAN borçsuzdur.

Borcun Azaltılması: KAN şirketinin 5 yıl önce borç/öz sermaye oranı 44.4% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: KAN şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: KAN serbest nakit akışı her yıl % 5.2 1.5 yıl yetecek nakit akışına sahip olacaktır.

Kancera Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully

Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

We Think Kancera (STO:KAN) Can Afford To Drive Business Growth

We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely

Recent updates

Chief Executive Officer recently bought kr225k worth of stock

New major risk - Market cap size

Kancera AB (Publ) Announces Chief Medical Officer Changes

Kancera AB (Publ) Provides Operational Update Concerning Its Clinical Development Program

New minor risk - Share price stability

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Kancera AB's Fractal Study Results to Be Presented at the ESC 2024 Conference

New major risk - Financial position

Kancera AB (publ) Announces Executive Changes

Kancera AB (publ) Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects

New major risk - Shareholder dilution

Forecast breakeven date pushed back to 2025

Kancera AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 73.011989 million.

New major risk - Financial position

New major risk - Share price stability

Kancera AB (publ) Reports Positive Top Line Results from the FRACTAL Study

We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully

Forecast breakeven date moved forward to 2024

Kancera AB (publ), Annual General Meeting, May 27, 2024

Kancera AB (publ) Receives Finnish Regulatory Agency Approval for Phase I Study of KAND145

Kancera AB (publ) Appoints Markus Jerling as Chief Medical Officer

Kancera AB (publ) to Report Q3, 2023 Results on Nov 17, 2023

New major risk - Share price stability

Kancera AB (Publ) Announces Newly Published Research Publication Confirms the Potential for Kancera's Fractalkine Blocker KAND567 in Cardiovascular Disease

Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

Kancera AB (publ) Reports Dosing of First Patient in the KANDOVA Study

Kancera AB (publ) Appoints Peter Selin as New Chief Executive Officer, Effective from July 1 2023

Independent Director recently sold kr58k worth of stock

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Forecast to breakeven in 2025

Kancera AB (publ) Submits Regulatory Application to the Swedish Medical Products Agency to Conduct Clinical Studies of KAND567 in Ovarian Cancer

Insufficient new directors

Kancera AB (publ) Reports New Preclinical Results Supporting Potential for Its Ror1 Inhibitor in B-Cell Malignancies

Kancera AB (publ) Reports Promising Preclinical Results from Studies of Its Fractalkine Axis Blocking Drug Candidates in B-Cell Lymphoma

Kancera AB (publ) Reports Good Progress of Recruitment in Ongoing Phase IIa Study of Kand567 in Myocardial Infarction and the Decision to Allow for Recruitment of Additional Patients

Kancera AB (publ) Reports Convincing Preclinical Results and Decision to Initiate Clinical Development of KAND567 in Ovarian Cancer

We Think Kancera (STO:KAN) Can Afford To Drive Business Growth

Insufficient new directors

We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely

Insufficient new directors

Here's Why We're Watching Kancera's (STO:KAN) Cash Burn Situation

First quarter 2021 earnings released: kr0.029 loss per share (vs kr0.56 loss in 1Q 2020)

Insider recently bought kr65k worth of stock

We're Not Very Worried About Kancera's (STO:KAN) Cash Burn Rate

Full year 2020 earnings released: kr0.13 loss per share (vs kr0.18 loss in FY 2019)

New 90-day low: kr1.62

Here's Why We're Not Too Worried About Kancera's (STO:KAN) Cash Burn Situation

New 90-day low: kr2.23

New 90-day low: kr2.37

Kancera AB (publ) to Report Q3, 2021 Results on Nov 19, 2021

New 90-day high: kr3.98

First half earnings released

New 90-day high - kr2.96

Oncopeptides AB (publ) (OM:ONCO) agreed to acquire Kancera's drug development facility in Solna, Sweden.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin